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Introduction
Colorectal neoplasm (CRN) is becoming a leading burden of disease worldwide [1] . More advanced clinical interventions including screening and chemotherapeutic treatment have been developed for CRN, but most of them are costly. Economic evaluation using cost-effectiveness analysis is commonly used to appraise clinical interventions to inform resource allocation. Quality-adjusted life-years are used as a general measure of health effects to capture both morbidity and mortality [2] . The "Q" quality adjustment weight of the quality-adjusted life-year, ranging from 0 for death to 1 for perfect health, is calculated by using a preferencebased valuation of health elicited by direct or indirect methods [3] . Direct valuation techniques, such as standard gamble or time trade-off of colorectal cancer (CRC) health states [4] , can be used to elicit utility values from patients for their own health, but its validity is questioned [5, 6] on the grounds that utility should be judged by society as a whole. An alternative method is the use of preference-based measures that have been valued by the general population, for example, the EuroQol five-dimensional (EQ-5D) questionnaire [7] and the six-dimensional health state short form (derived from short form 36 health survey (SF-6D) [8, 9] . The EQ-5D questionnaire is recommended by the National Institute of Health and Clinical Excellence [2] and is widely used in Europe. The SF-6D derived from health states measured by Medical Outcomes Study SF-36 Health Survey [8] is more popular in the United States and Asia. Population-specific scoring algorithms for SF-6D are available for the United Kingdom [8, 9] , Japan [10] , Portugal [11] , Hong Kong [12] , and Brazil [13] .
Condition-specific health-related quality-of-life (HRQOL) measures are usually not preference based. "Mapping" the generic or condition-specific HRQOL measures onto generic preferencebased measures is a method that can be used to predict utility values even though the preference-based measure was not included in the study. Mapping involves two stages. First, regression analysis is used to estimate the relationship between the "source" non-preference-based measure and the "target" preference-based measure. Second, this relationship can be applied to a study data set containing the source measure to predict. In recent years, numerous studies have successfully developed functions mapping from non-preference-based instruments onto EQ-5D questionnaire and SF-6D preference-based values in different patient groups [14 -16] ; see Brazier et al. [17] for a recent overview. Most studies in the literature have mapped onto the EQ-5D questionnaire [17] . Yet studies mapping onto both the EQ-5D questionnaire and SF-6D found that the models mapping onto SF-6D had better predictive performance than did those mapping onto the EQ-5D questionnaire [14, 15] .
The Functional Assessment of Cancer Therapy-Colorectal (FACT-C) is a popular HRQOL measure specific for CRN. Its psychometric properties were tested and confirmed in Chinese patients with colorectal polyps or cancer [18] . The FACT-C is an extended version of the FACT-General (FACT-G), which makes up four of the five subscales of the former. Mappings from FACT-G or FACT-C onto SF-6D provide a useful function for converting profile HRQOL scores collected by these condition-specific measures commonly used in cancer clinical trials to preference-based values for the calculation of quality-adjusted life-years for cost-effectiveness analysis.
Mapping studies often incorporate demographic and clinical characteristics into model estimation to increase a model's predictive performance [16,19 -21] . Demographics (age and gender) and tumor stage of CRN variables were included in the analysis. The aim of this study was to map from FACT-G and FACT-C subscale scores to SF-6D preference-based values in patients with CRN, with and without adjustment for clinical and demographic characteristics. The mapping function allowed researchers to conduct health economic appraisals of preventive screening and treatment program for CRN.
Methods

Subjects
All Chinese patients 18 years or older with a histology of confirmed colorectal polyp or cancer for at least 6 months were recruited from specialist outpatient medical and surgical colorectal clinics of a regional hospital in Hong Kong between October 2009 and September 2010. Patients were excluded if the doctor judged their life expectancy to be less than 6 months; they were unable to communicate in Cantonese; they had a known cognitive impairment; or they were too ill to participate in an interview. A total of 575 patients were invited to participate and of these 20 were unreachable and 2 withdrew, meaning 553 subjects were successfully interviewed via telephone (449 subjects) or face to face (104 subjects) by trained interviewers. Clinical characteristics such as tumor stage, treatment status, and colostomy status were retrieved from the medical records of patients. The CRN was classified into six stages on the basis of screening surveillance guideline [22] and American Joint Committee on Cancer (AJCC) staging system [23] : 1) low-risk polyps group (patients with Յ2 adenomas or 3-4 adenomas all of which were not larger than 1 cm), 2) high-risk polyps group (patients with Ն5 adenomas or with Ն3 adenomas at least one of which was larger than 1 cm), 3) stage I CRC, 4) stage II CRC, 5) stage III CRC, and 6) stage IV CRC. The tumor stage of CRN was classified as unknown if it was not specified in the medical record. Demographic and clinical characteristics of the patients are presented in Table 1 . Patients had an average age of 63.2 years (SD: 11.3) and 42.0% were females. For the stage of CRN, the mode was "stage III" with a percentage of 20.6%; the proportions of the other stages ranged from 13.0% to 18.3%. Among all patients, eight subjects (1.4%) had unknown stage of diagnosis and were excluded before the regression analysis of the mapping functions of SF-6D.
Data collection
Preference-based value and condition-specific HRQOL data were collected by using the Hong Kong Chinese version of SF-6D and traditional Chinese (Hong Kong) FACT-C Version 4, respectively. These instruments were administrated by trained interviewers at the same time. Clinical data were obtained from the doctors or extracted from the medical records of patients [24] . This study was approved by institutional review boards at the University of Hong Kong and Hospital Authority Hong Kong West Cluster (IRB Ref# UW 09-391).
Study instruments
FACT-G, developed by the Center on Outcomes, Research and Education [25] , is widely used to measure HRQOL for cancer patients in clinical trials. It is the core member of FACT instruments including four subscales: 1) 7-item physical well-being (PWB), 2) 7-item social/family well-being (SWB), 3) 6-item emotional well-being (EWB), and 4) 7-item functional well-being (FWB). FACT-C (Version 4) is the CRC-specific member of FACT instruments that includes the four FACT-G subscales plus a 9-item colorectal cancer subscale (CCS) that addresses additional concerns on quality of life for CRC [26] . All items have five response options ("not at all," "a little bit," "somewhat," "quite a bit," and "very much"). Each domain has a subscale score where higher scores indicate better HRQOL. Both FACT-G and FACT-C are designed for either patient self-completion [25] or interviewer administration [18, 27] . They can be admin- istered face to face or on telephone by trained interviewers [25] . The traditional Chinese version of FACT-C has been shown to be valid and reliable in Chinese patients with colorectal polyps or CRC in Hong Kong [18] . The SF-6D is a preference-based measure of health consisting of six aspects of health dimensions-physical functioning, role limitations, social functioning, pain, mental health, and vitality; each dimension is classified into four to six levels, giving a total of 18,000 combinations of health states. The SF-6D was originally developed by Brazier et al. [8] . It was translated into the Hong Kong Chinese version by Lam et al. [12] , which was validated and valued in the Hong Kong general Chinese population by using standard gamble [12, 28] . The Hong Kong population-specific preference scoring algorithm was used in this study here because these preferences are most representative of this patient population. The Hong Kong Chinese version of the SF-6D can be administrated by self or an interviewer [29] . Telephonic interview was acceptable to administer SF-6D because our preliminary analysis showed that the SF-6D values difference between telephone (449 subjects) and face-to-face (104 subjects) interviews was not statistically significant (P ϭ 0.152) by nonparametric Mann-Whitney U test.
Statistical analysis
Model specification
Model specification was informed by prior descriptive analysis of all variables. Separate models were estimated by mapping FACT-C and FACT-G onto SF-6D. Models were estimated by using 1) FACT variables using main effects, 2) as per point 1 plus squared terms, 3) as per point 1 plus interaction terms, and 4) as per point 3 plus clinical and demographics variables. Additional variables were added by using the stepwise regression technique. Ordinary least square method was used for all analysis. The F test was used to retain variables with an inclusion criterion of P value lower than 0.05 and exclusion criterion of P value greater than 0.10. Lower-order main effect terms (first order) were retained in the model even if their effects became insignificant when squared and interaction terms (second order) were added because of the principle of hierarchy. To ensure comparability of different models, only subjects with complete data (n ϭ 537) across all variables were used in the analysis.
Model comparison R
2 and the adjusted R 2 (Adj R 2 ) statistics were used to measure the explanatory power of each model, that is, how much of the variability in the dependent variable was explained by the predictors. In addition, predicted R 2 (Pred R 2 ) was calculated by one minus a fraction of predicted residual sum of squares over total sum of squares, which is more able than R 2 to assess the performance of a model for predicting new observations [30] . Of prime importance for selecting between models is predictive performance. Models with low errors are preferred because this implies that the model will have better predictive performance when used in other data sets to predict SF-6D. To assess the predictive ability of a model, the differences between the predicted and observed SF-6D values at the individual level were examined by computing the root mean square error (RMSE) and the mean absolute error (MAE). In addition, the number of observations and the corresponding proportions in the full sample that the absolute error (AE) was greater than the threshold of 0.05 and 0.10 for each individual were calculated, respectively. The goodness of fit of the model was described by using Akaike information criteria and Bayesian information criteria statistic. The achievable ranges of the SF-6D preference-based values from the resulting mapping functions were compared with the observed range of the SF-6D values. Residual plots for the final models were used as the primary tool to examine model adequacy such as the non-normality and heteroscedasticity.
Model validation
The validity and robustness of the mapping functions were assessed by using the 10-fold cross-validation procedure [20] . The full sample was randomly split into 10 equally sized groups. Each combination of nine groups formed a training data set that was used to estimate the parameters of the regression model, while the remaining group was considered as a test data set that examined the errors of prediction of the model generated by the training data set. The test data set was validated by inputting the independent variables of each observation of the test data set into the model fitted by the training data set. Differences of the observed value of the dependent variable from the predicted value calculated from the model were the error of prediction. The above procedure was repeated until all the 10 possible training data sets were tested. The errors of prediction for all observations were obtained to calculate the RMSE, MAE, and percentages of AEs greater than 0.05 and 0.10 (AE Ͼ 0.05 and AE Ͼ 0.10).
All regressions and other statistical analyses were conducted by using the SPSS, Version 18.0 (SPSS, IBM, Inc., Chicago, IL).
Results
Descriptive statistics for SF-6D and FACT-C
Observed SF-6D and FACT-C/FACT-G subscale scores of the subjects are shown in Table 2 . The mean score of SF-6D was 0.825 (SD: [28] . There was no floor effect in measuring the SF-6D score in the sample while a slight ceiling effect was observed, with 4.28% of patients having the best possible level of health state value of 1. There were no floor effects observed in the subscales except a very small one in SWB (0.37%). Ceiling effects were observed in all FACT-C subscales, with the highest found in PWB (40.22%). Table 3 shows the results of the analyses with FACT-G subscales scores. The main-effect terms selected from the FACT-G subscale scores in the first model (model G1) were PWB, EWB, and FWB. All the squared terms of PWB, EWB, and FWB scores were included in the second model (model G2) whereas their no interaction terms were significant (model not shown). Tumor stage and sex were eventually added to the model in the last model (model G3). Although PWB, EWB, and FWB contributed significantly in the first model (model G1), the effects of the main-effect terms of EWB and FWB became insignificant after the squared terms were added in the second model (model G2). Sex but not age was significant in the final model (model G3). The effects of tumor stage were significant except the subgroup effect of "high-risk polyps." The final model had a R 2 of 59.98%, an Adj R 2 of 59.07%, and a Pred R 2 of 57.22%. RMSE and MAE were 0.086 and 0.067, respectively. The percentage of AE greater than 0.05 was 51.58% while that of AE greater than 0.10 was 23.84%. The fitted range of the SF-6D preference-based values estimated for the mapping function was 0.491 to 1.038, the lower bound of which was 0.11 more than that of the observed SF-6D range (0.385-1). The scatter plot of mean observed and predicted SF-6D preferencebased values by the health state ranking in descending order of the mean observed values (Table 5 and Fig. 1 ) indicates overprediction for more severe health states, where observed SF-6D value was less than 0.8.
Regression modeling of the FACT-G-based mapping function
The performance of model G2 without the demographic and clinical variables was only slightly inferior to that of the final model, with an adjusted R 2 of 58.1%, and favorable RMSE, MAE, and AE proportions.
Regression modeling of the FACT-C-based mapping function
Mapping function of FACT-C subscales scores is shown in Table 4 . Similar to the model for FACT-G, PWB, EWB, and FWB scores were selected as the main-effect terms in first model (model C1) to which was added the CCS. Among the four squared terms, PWB2 and EWB2 entered the model in the second model (model C2). EWB2, however, was removed from the model in the third model (model C3) that integrated the interaction terms of PWB ϫ FWB, EWB ϫ CCS, and FWB ϫ CCS. In the final model (model C4), tumor effects of "high-risk polyps," "stage I CRC," and "stage III CRC" were insignificant. The final model achieved a R 2 of 61.65%, an Adj R 2 of 60.63%, a Pred R 2 of 58.41%, and the smallest Akaike information criteria among prediction models. RMSE and MAE ; PWB, physical well-being; RMSE, root mean square error. * Significant with P Ͻ 0.05. † Stage IV is the reference category of colorectal neoplasm staging.
were 0.084 and 0.065, respectively, which were better than for the FACT-G-based model. The percentage of AE greater than 0.05 was 48.98% while that of AE greater than 0.10 was 22.53%. The fitted values of SF-6D ranged from 0.462 to 1.022, the lower bound of which was 0.077 more than that of the observed range (0.385-1). The scatter plot of observed and predicted SF-6D preference-based values by FACT-C-based mapping function is also shown in Figure 1 . A similar pattern of overprediction is observed for SF-6D values lower than 0.8, as demonstrated in Table 5 . The mapping function of SF-6D using four scores of the FACT-C subscale (model C3) produced acceptable model performance with less than 50% of subjects with AE greater than 0.05 and the smallest Bayesian information criteria. Table 6 shows the prediction errors in the 10-fold cross-validation procedure. The RMSE and MAE were estimated to be 0.089 to 0.092 and 0.069 to 0.071, respectively, in FACT-G-based models and 0.088 to 0.091 and 0.068 to 0.070, respectively, in FACT-C-based models. The percentage of AE greater than 0.05 was between 50.28% and 56.04% while that of AE greater than 0.10 was between 23.07% and 24.02%. Mean SF-6D values predicted by FACT-G/ FACT-C based on cross-validation were 0.825, which were consistent with the actual SF-6D values. Validation results of applying our mapping functions to patients with CRN suggested that both models predicted SF-6D preference-based values accurately.
Model validation
Discussion
Mapping functions have been previously developed by using data from patients with general cancer [31, 32] , esophageal cancer [33] , gastric cancer [15] , and prostate cancer [20] . This study is the first attempt, to our knowledge, to develop a mapping function to estimate SF-6D preference-based values from condition-specific measures for patients with CRN. The results from a relatively large sample of 537 patients with different disease severity confirmed that SF-6D preference-based values can be estimated from FACT-G/FACT-C subscale scores by using mapping functions. A 10-fold cross-validation was performed to strengthen their validity and robustness. Our findings suggested that the mapping of a more specific measure (FACT-C) had better performance than that of the general cancer measure (FACT-G), probably because it has the additional scale that captures the HRQOL domain specific to our CRN patient sample. Final models adding significant square terms, interaction terms of the subscales, and tumor stage and demographic variables into the main-effect models had slight improvements in the model performance (about 3%-6% increment in R Predictive performances of the preferred models of FACT-G/ FACT-C were good using statistical criteria and standards achieved by previous mapping studies. A review of mapping studies [17] found that only 4 of 30 models that reviewed mapping a condition-specific measure to a generic health preference-based measure achieved an R 2 of 60%. The R 2 value of our final FACT-Gbased model was approximately 60%, and the R 2 of two of our FACT-C-based models exceeded 60%. On the whole, the R 2 , Adj R 2 , and Pred R 2 of all models were greater than 50%, which represented acceptable explanatory power. The predictive performance of the models was also supported by the small proportion (Ͻ0.10) of predictions with MAE and RMSE, and for each model less than a quarter of the sample had an AE of more than 0.10. Table 5 shows the mean error, RMSE, and MAE of predicted compared with actual preference-based values by SF-6D range for FACT-G/FACT-Cbased prediction models. When comparing the ranges of the fitted values of both mapping functions to the observed range of SF-6D values, a tendency of overprediction was observed in each model for observed value of SF-6D less than 0.8 ( Table 5 ). The size of mean error in this article varied across the SF-6D range, with larger errors when the SF-6D value was below 0.8. The mean errors in that range were larger than 0.03, which was the proposed minimally important difference for SF-6D scores [34] . Overprediction of low preference-based values also occurred in the literature mapping onto a variety of preference-based measures including the EQ-5D questionnaire [21, 35, 36] .
A recent literature review [17] found that MAE reached 0.19, representing around 15% of the possible range of the preferencebased measure. This problem has been commonly found in the use of mapping function to estimate preference-based values rather than measuring a preference-based measure directly in the study of interest. It is important that the uncertainty around the mapped estimates should be taken into account in the cost-effectiveness model and research is ongoing in this area.
Several previous studies developed the mapping functions from a condition-specific measure onto the EQ-5D questionnaire preference-based measure by censored least absolute deviations (CLAD), tobit, and standard two-part regressions [32, [37] [38] [39] [40] because the EQ-5D questionnaire suffers from high ceiling effects. Low ceiling effect observed from our SF-6D data, however, did not support the use of these models. A study by Cheung et al. [32] that mapped FACT-G onto preference-based values measured by the EQ-5D questionnaire achieved a model with R 2 of 45.0%, which was lower than the R 2 in our FACT-G-based mapping functions. In accordance with Cheung et al. [32] , the PWB, EWB, and FWB but not SWB subscale scores were the significant variables in our regression models of FACT-G-based mapping functions. Our mapping functions had better predictive performance than did the models estimated by Cheung et al. [32] , which could be due to a more homogenous patient population and within-sample testing in our study. Another reason for a higher explanation performance of our models was the inclusion of clinical and demographic variables that were not included in their models. Furthermore, the ceiling effects of SF-6D are lower than those of the EQ-5D Questionnaire, which could also lead to a difference in the performance of the mapping functions [41] .
Although the ordinary least square regression is the most common mapping approach [17] , it is limited to the normality and homoscedasticity assumptions for residuals. Because of the ceiling effect of the SF-6D preference-based measure, a small extent of violation of the normality and homoscedasticity assumptions was indicated by the residual plots of the regression models, which might have caused some biases in our coefficient estimates. Alternative mapping methods such as response mapping [42] and probabilistic mapping [43] have been used to map the Short Form 12-Item (SF-12) onto EQ-5D Questionnaire responses by others. Each EQ-5D Questionnaire dimension is classified into three response levels to allow sufficient amount of subjects for model development. However, our SF-6D data fitted poorly to these models because only a few subjects reported the worst response level in the SF-6D dimensions: physical functioning (3, 0.5%), pain (4, 0.7%), mental health (1, 0.2%), and vitality (8, 1.5%).
Limitations
Our results from Chinese patients with CRN may not be applicable to non-Chinese populations, not least because the SF-6D values predicted by the models are based on Hong Kong preferences weights. Furthermore, our models were developed for a homogeneous CRN patient population, which may not be generalizable to other cancer patient groups. It should be with caution that the model developed in this study should be validated on another sample before fitting on other data sets. In addition, the exclusion of ill patients might be the reason for the high ceiling effect observed on the PWB subscale, leading to high mean SF-6D values of 0.825. This might also be explained that most of the patients were long-term survivors with diagnosis of neoplasms for more than 6 months.
Conclusions
Mapping of FACT-G/FACT-C subscale scores onto SF-6D preferencebased values reached an acceptable degree of precision for Chinese patients with CRN. The best models for the estimation of SF-6D preference-based value included the FACT-G/FACT-C subscale scores, sex, and tumor stage. These mapping functions can be applied to FACT-G/FACT-C data sets to predict SF-6D utility values for use in cost-effectiveness analysis of medical interventions for patients with CRN. Further studies on non-Chinese populations and different cancer patient groups are needed to validate the applicability of our mapping functions before wider applications.
